SCHEMBL6485532

SCHEMBL6485532

CC(C)(C)OC(=O)N1CCC(Cc2nnnn2C(c2ccccc2)(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
PKM P14618 1/20 0.50
GPR119 Q8TDV5 7/20 0.47
THRB P10828 2/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
STS P08842 1/20 0.43
TGFBR1 P36897 1/20 0.42
TP53 P04637 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
KDM1A O60341 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LIMK2 P53671 1/20 0.41
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482957 0.91 KDM4E (0.49) KDM4EPKMGPR119THRBGAA
SCHEMBL6476320 0.83 LMNA (0.47) GPR119THRBTP53LMNAMAPT
SCHEMBL6484529 0.82 CHRM2 (0.46) GPR119MAPTNAMPT
SCHEMBL3923737 0.76 KDM4E (0.64) KDM4EPKMGPR119STSTP53
SCHEMBL1088570 0.74 GPR119 (0.61) KDM4EPKMGPR119THRBSMN1; SMN2
SCHEMBL29566603 0.74 GPR119 (0.61) KDM4EPKMGPR119THRBSMN1; SMN2
SCHEMBL18279997 0.72 KDM4E (0.59) KDM4EPKMGPR119STSTP53
SCHEMBL2867370 0.72 GPR119 (0.53) KDM4EPKMGPR119SMN1; SMN2STS
SCHEMBL20601445 0.72 KDM4E (0.68) KDM4EPKMGPR119STSTGFBR1
SCHEMBL24983989 0.72 KDM4E (0.50) KDM4EPKMGPR119STSTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1312153-C Pyrrolopyrimidinone derivatives, process for their preparation and their use SK CHEMICALS CO LTD (KR) 2007-04-25 CN disclosed
US-6962911-B2 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2005-11-08 US disclosed
EP-1257553-B1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK CHEMICALS CO LTD (KR) 2004-05-26 EP disclosed
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2003-09-11 US disclosed
CN-1422271-A Pyrrolopyrimidinone derivatives, process for their preparation and their use SK CHEMICALS CO LTD (KR) 2003-06-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use CYP2C19, DHPS, SDHA KDM4E 1887/4885PKM 91/4885GPR119 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.